Companies
Schweizer Exporte fallen im August um 17,2%
Nach einem Vormonatsrekord brach die Schweiz im August 2026 saisonbereinigt Exporte um 17,2% ein, getrieben durch ein Einbruch in der Chemie- und Pharmaindustrie, während Maschinen- und Metallsektor leichte Zuwächse verzeichneten.
FINMA Urges Legal Reforms to Strengthen Banking Resilience Amid Global Uncertainty
Swiss financial regulator FINMA emphasizes the need for preventive measures and transparency in enforcement to address governance failures and systemic risks in banking, while calling for legislative updates to bolster compliance tools.
FINMA’s Risk-Based Supervision: Tailored Approach for Small Banks
FINMA emphasizes proportionality in its oversight of smaller banks, aligning supervisory intensity with systemic risk rather than size alone. The Swiss regulator highlights targeted relief for stable, well-capitalized institutions while maintaining rigorous enforcement for high-risk categories.
Infracore Expands Hospital Wetzikon Financing Offer
Real-estate investor Infracore extends its acquisition offer for Spital Wetzikon real estate to October 2026 and commits fallback financing to operator GZO AG.
Genentech's Lunsumio Regimen Meets Primary Endpoint in Follicular Lymphoma Trial
Genentech reported that its Lunsumio plus lenalidomide combination met the primary endpoint in the Phase III CELESTIMO study, showing significantly improved progression-free survival in relapsed/refractory follicular lymphoma.
OpenAI discloses 6 cases of misaligned AI model behavior
OpenAI released six instances of "misaligned" model behavior discovered over the past six months, adding to growing concerns among AI developers about whether safety safeguards can keep pace.
Roche's Lunsumio regimen clears hurdle in follicular lymphoma phase III trial
The phase III CELESTIMO study met its primary endpoint, showing significantly improved progression-free survival in relapsed/refractory follicular lymphoma patients receiving at least one prior treatment.
Akkodis Appoints Giles Guidicelli to Lead Germany and Austria Operations
The digital engineering unit of the Adecco Group has named the technology veteran as Group SVP, effective September 1, with Thomas Klukas moving to a global role.
Asian currencies mixed as dollar holds seven-week high, yen steadies
Asian currency markets showed mixed movements while the U.S. dollar remained at a seven‑week peak and the Japanese yen held steady.
Akkodis names Giles Guidicelli managing director for Germany and Austria
The global digital engineering firm appoints Guidicelli, formerly of Capgemini Engineering, to lead its German and Austrian operations starting September 1, 2026.
Banks pledge $22 bn to fund Google‑Blackstone AI cloud venture
A consortium of ten banks will provide $22 bn in financing for Crux AI, the cloud joint venture of Alphabet and Blackstone, to purchase Google’s Tensor Processing Units and build 500 MW of data‑center capacity by 2027.
Hailstorm Leaves Nearly 1 Billion Francs in Insured Losses Across Swiss Midland
The Swiss Insurance Association estimates insured damages from late-August hail and storm at almost 1 billion francs, with over 80% hitting motor vehicles.
US Regulator Challenges Tesla Cybercab Over Missing Steering Wheel and Pedals
The NHTSA has demanded answers from Tesla on how its pedal-free Cybercab meets federal safety rules, with fines of up to $139 million looming if the automaker fails to comply by late September.
Why Switzerland Is Becoming an Unexpected Hub for Big Tech’s AI Billions
Artificial intelligence is usually associated with Silicon Valley.
New York Times Sets 15M Subscriber Target for 2027, Accelerates Video Strategy
At Citi's 2026 Global TMT Conference, NYT CFO Will Bardeen outlined a video-first push and a path to 15 million total subscribers by end of 2027, citing strong digital ad performance and expanding reach beyond 150 million users.
Unilever Charting EUR39bn Pure-Play Home & Personal Care Transformation
CEO Fernando Fernandez outlines portfolio reshaping at Barclays conference, citing McCormick food-unit combination and Magnum ice-cream separation as key moves.
First Tracks Biotherapeutics Outlines ANB033 Pipeline at Wells Fargo Health Conference
Biotech spinner-out from AnaptysBio details CD122 antagonist data milestones for celiac, EoE, and lupus, with cash runway into Q2 2028.
Swiss Hailstorm Causes Nearly SFr1 Billion in Insured Losses
August 2026 hailstorm across the Swiss Mittelland damaged over 100,000 vehicles, with claims roughly double the magnitude of the 2023 Ticino event.
Cardinal Health Specialty Revenue Tops $50 Billion; EPS Guidance Raised
Cardinal Health's specialty segment crossed a $50 billion revenue milestone, and the company raised its fiscal 2027 adjusted EPS growth outlook to 13-15%, citing double-digit segment growth and M&A contributions.
Clorox Sets Modest Growth Targets as It Navigates Cost Pressures and Leadership Change
Clorox raised its fiscal 2027 organic sales growth outlook to 3.5%-4.5% at a Boston conference, but underlying growth is expected to be flat to slightly up, weighed by persistent input cost inflation exceeding $200 million.
Parsons reports booking surge, $11B pipeline at Jefferies industrials conference
Parsons CEO Carey Frazier said the company’s federal bookings jumped 45% year-over-year with a book-to-bill above 1.3 in Q2, while awarded-but-not-yet-booked contracts reached $11 billion.
Huang Says Hyperscalers Misjudge Demand; Nvidia Shifts to Regional Clouds
Nvidia CEO Jensen Huang argues hyperscalers' annual planning cycle leaves them behind fast-moving AI demand, prompting the company to back a distributed network of neocloud providers.
FedEx Launches Digital Suite for International Shipping
FedEx introduced new global trade tools aimed at reducing surprises around duties and taxes for shippers, based on data showing significant revenue losses from cross-border complexities.
Tango Therapeutics' Vopimetostat Clears Hurdle Toward Pancreatic Cancer Approval
Shares of Tango Therapeutics rose after the company reported a 92% response rate for its lead PRMT5 inhibitor in combination with Revolution Medicines' daraxonrasib, and confirmed its cash runway extends through commercial launch.